N ANTHONY COLES
CIK 1197018 · CEO and Chairperson · last filed 2026-01-06
N ANTHONY COLES is a CEO and Chairperson who has filed 103 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for REGN, was dated Jan 6, 2026. Across all open-market trades the lifetime net is −$78.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.3M across reported positions. 17 SEC filings were submitted jointly with REGENERON PHARMACEUTICALS, INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.28M
10
103
-$78.50M
Filer Profile
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| REGN | Director | 1,714 | $781.49 | $1.34M | -$20.62M | 16 | 2026-01-06 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Director | 25,928 | $44.96 | $1.17M | -$30.40M | 22 | 2024-07-03 |
| KINETA, INC./DE (YMTX) Delisted | Executive Chair | 106,239 | $13.23 | $1.41M | $0 | 3 | 2021-04-02 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | President and CEO | — | $18.07 | — | $0 | 2 | 2021-02-05 |
| MCK | Director | 0 | $881.51 | $0 | -$558.3K | 9 | 2020-08-19 |
| CRISPR Therapeutics AG (PZRX) Delisted | Director | 70,000 | — | — | $0 | 3 | 2017-06-02 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | Chairman & CEO | 131,198 | — | — | -$26.92M | 17 | 2013-06-07 |
| Campus Crest Communities, Inc. (RLD) Delisted | Director | 3,999 | — | — | $0 | 4 | 2013-05-31 |
| LH | Director | 3,008 | $311.54 | $937.1K | $0 | 4 | 2013-02-19 |
| NPS PHARMACEUTICALS INC (NPSP) Delisted | President, COO & Director | 147,638 | — | — | $0 | 7 | 2008-03-18 |
Recent Filings
103 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-06 | REGN | Grant (A) | +155 | $0 | EDGAR |
| 2025-01-06 | REGN | Grant (A) | +166 | $0 | EDGAR |
| 2024-08-05 | — | Disp (D) | −25,928 | $0 | |
| 2024-07-03 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Mixed | — | -$942.0K | EDGAR |
| 2024-07-01 | — | Notice (144) | −25,000 | -$1.02M | EDGAR |
| 2024-06-07 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Grant (A) | +10,290 | $0 | EDGAR |
| 2024-06-05 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Mixed | — | -$1.86M | EDGAR |
| 2024-06-03 | — | Notice (144) | −50,000 | -$2.04M | EDGAR |
| 2024-05-14 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Mixed | — | -$1.93M | EDGAR |
| 2024-05-10 | — | Notice (144) | −50,000 | -$2.12M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.